US FDA
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
If US FDA is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Late diagnosis and systemic gaps drive high cancer death rates in the Balkans · The Medical News · 2026-09-29
- AB Science’s “Calendar Update” Is a GCP Inspection Disclosure in Disguise · The Clinical Trial Vanguard · 2026-09-29
- A review of FDA warning letters based on historical advertising (part I) · Nutraceutical Business Review · 2026-09-29
- Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC · Clinical Trials Arena · 2026-09-28
- FDA grants breakthrough designation to Glytec’s Glucommander Pediatrics · Medical Device Network · 2026-09-25
- US FDA Approves AbbVie’s Once-Daily Parkinson’s Disease Drug Tavapadon · Voice of Healthcare · 2026-09-29 · usually covers Precision Medicine
What the reporting says
Across 22 tracked stories from 12 outlets, reporting on US FDA most often describes regulatory approvals (13).
It shows up alongside FDA (22), US Food (9), Drug Administration (9).
Two steps out: AI (through FDA, 22 shared stories on the weaker link); Cder (through FDA, 22 shared stories on the weaker link); China (through FDA, 22 shared stories on the weaker link); Clinical Trial (through FDA, 22 shared stories on the weaker link).
Tracked since Apr 14, with coverage on 15 separate days — concentrated in Medical Devices and Auto.